Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.
about
Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next LevelIs it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study.Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future DirectionsSafety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trialPotential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.Influence of Adjuvant Therapy in Cancer Survivors on Endothelial Function and Skeletal Muscle Deoxygenation.Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy.Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions.Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant ChemotherapyThe potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA).Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic trainingBenefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer.Noninvasive early detection of anthracycline-induced cardiotoxicity in patients with hematologic malignancies using the phased tracking method.Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking.Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance.Imaging methods for detection of chemotherapy-associated cardiotoxicity and dysfunction.Cardiotoxicity due to chemotherapy: role of cardiac imaging.Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.Chemotherapy-induced cardiomyopathy.Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity.Echocardiography and Alternative Cardiac Imaging Strategies for Long-Term Cardiotoxicity Surveillance of Cancer Survivors Treated with Chemotherapy and/or Radiation Exposure.Altered Blood Flow Response to Small Muscle Mass Exercise in Cancer Survivors Treated With Adjuvant TherapyOptimizing cardio-oncology programs for cancer patients.Cardiac complications of chemotherapy: role of prevention.Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.[Overweight and obesity are risk factors for development of cardiotoxicity from anthracyclines or sequential administration of anthracyclines and trastuzumab].Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer.Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes.Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative.Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
P2860
Q26864094-1F7DAC03-9F7F-4BCA-95BE-9BE1CF7431AFQ30244600-74D38FB3-C578-4CF4-9581-7C6DEEB1DA20Q30401812-AFE636FD-5CA3-47FE-B1DF-94978B92E8A9Q33562971-1D24C718-3FB1-43A1-B948-10A8482870E9Q33907581-E5B4EC56-9B4F-47B2-8BF7-48921A44F7B2Q34001004-0CE640FB-0C2B-4333-8257-6AB509B00480Q34333236-A705D1AA-53AD-40C2-8F2C-EC11FEE47ADAQ35903018-0DEBAE40-AFC8-43E2-8E45-3D1ADD2A8DC5Q35905883-C779B718-A97A-492F-B484-C57D1A3A873FQ35957908-7AA8A881-FC8B-4FC5-87BD-18065CE7E845Q36085651-F3235774-F136-4EBA-BF96-53C448DF7C7EQ36551901-0589627B-1FF3-4892-B163-B68CA91CAA72Q36558438-B9909B1B-482D-46FC-BF84-EF093A0A2502Q36630478-E4716BD6-6C59-4D39-98BC-06CD604FBC47Q36729600-09D68266-9B50-410F-8558-02A1E546BA5AQ37116520-D395597B-E0F6-475B-8F5B-77C22A1CACD4Q37213203-295D393A-8B0A-42EB-85EB-9DAE64316405Q37311943-B9F684E7-3F5B-436B-9363-BE3D90D86F84Q37314505-33299604-FDDD-4739-BC1E-BA79E9BB6E2DQ37321045-B8E5D072-F6D5-4F6E-A23A-EDC73C0152E7Q37397983-6714657D-311D-4832-9F79-F742CE8D527DQ37719598-BE25CD82-C497-4AEA-A3C4-3E9BFF5821F1Q38197733-C40A5F24-1245-4AC8-8B51-607EAD8067FAQ38343043-4A82A7AD-7EAA-4C58-A210-E51B75E1D57DQ38559474-36E9E067-461C-4177-B15B-AAFA39CA97D1Q38580452-ADCECC7F-9F0C-4A75-972D-B2F6B4AA8FE9Q38717558-50262544-2D61-4FBC-BCCF-22D44E8E9E9CQ38773470-0F9AF98A-FA8F-452D-8FAA-E09EA207AE35Q38909573-585ED353-C13C-45A3-97C9-7450A7E4718FQ38973438-D5D238AB-9D4A-4555-ACA8-E2848CB13A41Q38982311-A9F023E6-6E0B-48D8-8C38-A1C3BDD6BD13Q39194543-372C3E3A-B0CE-4A50-8993-57CCE21BA509Q39683758-535C7243-ABA4-404C-B83A-EE5E438C16A8Q40365766-9AADAB97-6EDA-4A74-9DB3-35C9E7A1471DQ40739263-DFA3F8B2-0167-470D-B8D3-99C546ECB414Q41483888-C5280BAE-6A7D-4087-898F-D6976CFBE72FQ41728099-3B7D1286-2930-4BBC-9800-10EB0F803D8AQ42362046-30455FEF-3CDE-4681-914A-D7AE94E743EDQ45084464-EA247321-2EB0-462C-ADC9-4BBA57B0AB6DQ46941129-D33765DF-2C54-460F-A322-0422CF3A7028
P2860
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cancer therapy-induced cardiac ...... ressing the unresolved issues.
@en
type
label
Cancer therapy-induced cardiac ...... ressing the unresolved issues.
@en
prefLabel
Cancer therapy-induced cardiac ...... ressing the unresolved issues.
@en
P2093
P2860
P50
P1433
P1476
Cancer therapy-induced cardiac ...... dressing the unresolved issues
@en
P2093
Lee W Jones
Marielle Scherrer-Crosbie
Michel G Khouri
Pamela S Douglas
P2860
P304
P356
10.1161/CIRCULATIONAHA.112.100560
P407
P577
2012-12-01T00:00:00Z